Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission

[1]  M. Arosio,et al.  Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. , 1990, The Journal of clinical endocrinology and metabolism.

[2]  M. Salcedo,et al.  GSPα mutations in Mexican patients with acromegaly: potential impact on long term prognosis , 2005 .

[3]  E. Clementi,et al.  A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumours. , 1990, Oncogene.

[4]  D. Figarella-Branger,et al.  Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. , 1998, The Journal of clinical endocrinology and metabolism.

[5]  E. Codner,et al.  gps Mutations in Chilean Patients Harboring Growth Hormone-Secreting Pituitary Tumors , 1999, Journal of Pediatric Endocrinology & Metabolism (JPEM).

[6]  R. Fahlbusch,et al.  Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. , 1993, Neurosurgery.

[7]  H. Bourne,et al.  Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein. , 1990, The Journal of clinical endocrinology and metabolism.

[8]  K. Kovacs,et al.  Clonal origin of pituitary adenomas. , 1990, The Journal of clinical endocrinology and metabolism.

[9]  A. Arnold,et al.  Clinically nonfunctioning pituitary tumors are monoclonal in origin. , 1990, The Journal of clinical investigation.

[10]  M. Korbonits,et al.  Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. , 2001, The Journal of clinical investigation.

[11]  E. Hedley‐Whyte,et al.  Glycoprotein hormone alpha-subunit production in somatotroph adenomas with and without Gs alpha mutations. , 1992, The Journal of clinical endocrinology and metabolism.

[12]  D. Figarella-Branger,et al.  Pronostic and Therapeutic Consequences of Gsα Mutations in Somatotroph Adenomas1 , 1998 .

[13]  H. Bourne,et al.  GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours , 1989, Nature.

[14]  P. Chanson,et al.  The cyclic adenosine 3',5'-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. , 1995, Molecular endocrinology.

[15]  Y. Kim,et al.  Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. , 1996, European journal of endocrinology.

[16]  D. Bonthron,et al.  Imprinting of the Gsα gene GNAS1 in the pathogenesis of acromegaly , 2001 .

[17]  S. Melmed.  Mechanisms for pituitary tumorigenesis: the plastic pituitary. , 2003, The Journal of clinical investigation.

[18]  T. Sano,et al.  Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction—primer‐introduced restriction analysis , 1993, Cancer.

[19]  M. Salcedo,et al.  GSPalpha mutations in Mexican patients with acromegaly: potential impact on long term prognosis. , 2005, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[20]  A. Barkan,et al.  Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. , 1988, The Journal of clinical endocrinology and metabolism.

[21]  A. Barlier,et al.  Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. , 1999, The Journal of clinical endocrinology and metabolism.

[22]  M. Losa,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Constitutively Active Gs � Is Associated with an Increased Phosphodiesterase Activity in Human Growth Hormone-Secreting Adenomas* , 2022 .

[23]  Y. K. Choi,et al.  Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue , 1995, Clinical endocrinology.

[24]  D. Tang,et al.  Detection of gsp oncogene in growth hormone-secreting pituitary adenomas and the study of clinical characteristics of acromegalic patients with gsp-positive pituitary tumors. , 1998, Chinese medical journal.

[25]  H. K. Lee,et al.  Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas. , 2001, The Journal of endocrinology.

[26]  E. Kawasaki,et al.  Two G protein oncogenes in human endocrine tumors. , 1990, Science.

[27]  G. Giannattasio,et al.  Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas , 1987, Nature.

[28]  R. Fahlbusch,et al.  Clinical Correlates in Acromegalic Patients with Pituitary Tumours Expressing GSP Oncogenes , 1999, Pituitary.

[29]  T. Sano,et al.  Analysis of the Gs α gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues , 1993 .

[30]  M. Arosio,et al.  GS protein mutations and pituitary tumors: functional correlates and possible therapeutic implications. , 1996, Metabolism: clinical and experimental.